Novel System Enhances Bead-Based Multiplexing Assays Using Less Sample and Reagent While Achieving Optimal Cytokine Sensitivity Luminex cytokine assays are common bead-based multiplex ELISA assays ...
Luminex’s xMAP® Technology enables the evaluation of up to 500 analytes simultaneously in a single well, known as multiplexing. xMAP® Technology uses color-coded microspheres as the substrate on which ...
Luminex’s xMAP Technology will be deployed by the HPA project to perform flexible and high-throughput screening of biomarkers using the HPA antibodies on large numbers of samples. The same technology ...
AUSTIN, Texas, July 1, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has delivered the first of its new xMAP® INTELLIFLEX Systems to several of its Life ...
HATFIELD, PA.--(BUSINESS WIRE)--Data-driven food allergy diagnostics company, AllerGenis, LLC today announced that it has entered into a non-exclusive agreement with Luminex Corporation (NASDAQ: LMNX) ...
Luminex Corporation will unveil FlexMAP 3D™, its next generation bead-based multiplexing system, today at the American Association for Clinical Chemistry (AACC) Annual Meeting in San Diego. FlexMAP 3D ...
Rapidly evolving genomic technologies have spawned the Tm/Luminex Universal Array Platform, capable of reading 10,000 single nucleotide polymorphisms (SNPs) per hour. Distributed by Luminex of Austin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results